An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumor burden in mice bearing human castration-resistant prostate cancer, according to data presented ...
Apr 5, 2017
0
1
Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior ...
Apr 5, 2017
0
8
Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously ...
Apr 5, 2017
0
0
Although most patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) experienced complete response after treatment with a type of CAR T-cell immunotherapy, pretreatment disease burden impacted the durability of ...
Apr 4, 2017
0
0
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data ...
Apr 3, 2017
0
1
Among patients with metastatic triple-negative breast cancer (TNBC) who were treated with the anti-PD-L1 cancer immunotherapy atezolizumab (Tecentriq), those who responded to the medicine lived significantly longer (overall ...
Apr 3, 2017
0
3
The immunotherapeutic avelumab (Bavencio) was well tolerated by patients with advanced Merkel cell carcinoma, and the majority of those whose cancer responded to avelumab treatment had durable responses, according to results ...
Apr 3, 2017
0
0
Computed Tomography (CT) scans are a reliable tool to establish a diagnosis of immune-related colitis, a potentially life-threatening adverse event in patients with advanced melanoma who receive the immune checkpoint inhibitor ...
Apr 3, 2017
0
2
Patients with glioblastoma who wore a medical device that delivers alternating electrical fields in addition to being treated with the chemotherapeutic temozolomide had significantly improved median overall survival compared ...
Apr 3, 2017
0
1
A combination of two HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results ...
Apr 3, 2017
0
1
